Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 200

Results For "treatment"

3741 News Found

North India’s first government homoeopathic college coming up in Kathua: Dr. Jitendra Singh
Policy | March 11, 2024

North India’s first government homoeopathic college coming up in Kathua: Dr. Jitendra Singh

The institution will be spread over an area of more than 8 acres


LVPEI observes World Glaucoma Week
Healthcare | March 11, 2024

LVPEI observes World Glaucoma Week

Vision loss due to Glaucoma can be prevented if it is detected and treated early


Jagsonpal Pharmaceuticals launches QueeZy-ER
News | March 09, 2024

Jagsonpal Pharmaceuticals launches QueeZy-ER

The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation


Govt supports Alchem Synthon with Rs. 8.6 crore loan assistance for chemical production facility
News | March 07, 2024

Govt supports Alchem Synthon with Rs. 8.6 crore loan assistance for chemical production facility

The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities


EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer
Drug Approval | March 07, 2024

EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer

The validations confirm the completion of the applications and commence the scientific review process


Strides receives USFDA approval for Gabapentin Tablets
Drug Approval | March 06, 2024

Strides receives USFDA approval for Gabapentin Tablets

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty


Bayer strengthens pharma portfolio with new cardiology drug acoramidis
News | March 06, 2024

Bayer strengthens pharma portfolio with new cardiology drug acoramidis

Acquisition of exclusive commercialization rights for European markets


BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends
Clinical Trials | March 06, 2024

BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months


Govt.  setting up of Ayush - ICMR Advanced Centre for AI-ACIHR at select AIIMS
News | March 04, 2024

Govt. setting up of Ayush - ICMR Advanced Centre for AI-ACIHR at select AIIMS

Launch of Indian public health standards for Ayush healthcare facilities


Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease
Clinical Trials | March 03, 2024

Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg